Want to see UCBJY full AI Analyst Report?
UCBJY Stock Chart & Stats
$155.89
$1.86(1.89%)
At close: 4:00 PM EST
$155.89
$1.86(1.89%)
Day’s Range― - ―
52-Week Range$96.14 - $168.70
Previous CloseN/A
Volume2.14K
Average Volume (3M)2.85K
Market Cap
$56.35B
Enterprise Value$48.04B
Total Cash (Recent Filing)$2.47B
Total Debt (Recent Filing)$2.24B
Price to Earnings (P/E)32.3
Beta0.44
Next Earnings
Jul 30, 2026EPS Estimate
2.71Next Dividend Ex-DateN/A
Dividend Yield0.55%
Share Statistics
EPS (TTM)4.08
Shares Outstanding389,011,320
10 Day Avg. Volume1,843
30 Day Avg. Volume2,850
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)4.16
Price to Sales (P/S)6.08
P/FCF Ratio25.02
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue6.23
Enterprise Value/Gross Profit8.58
Enterprise Value/Ebitda18.49
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)6.26
Revenue Forecast (FY)$9.85B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationUCB’s material improvement in operating cash flow and ~44% FCF growth in 2025 indicates stronger cash earnings quality. Durable free cash flow supports sustained R&D funding, the planned U.S. manufacturing investment, debt reduction and optionality for M&A or shareholder returns over the next 2–6 months.
Improved Balance SheetEquity growth and notable debt reduction in 2025 materially improve financial flexibility and lower financing risk. The company reduced net financial expenses and deleveraged, strengthening the ability to absorb R&D spending, fund capex (including major manufacturing builds) and withstand industry headwinds without urgent refinancing needs.
High-growth Commercial PortfolioRapid scaling of five growth drivers (€3.3bn in 2025) and BIMZELX’s multibillion sales create a diversified, durable revenue base. Broad approvals, strong patient uptake and multiple indications reduce single-product concentration risk and underpin multi-year organic revenue growth and margin expansion prospects.
Bears Say
Margin Pressure / EBIT DeclineEBIT declining in 2025 while revenue rose signals margin compression from rising operating costs. Sustained higher M&S and R&D (management flagged increased spend) could limit operating leverage and cash conversion unless offset by mix shifts or price realization, risking durability of profitability gains.
Net-price / Gross-to-net PressureGrowing rebates and gross-to-net adjustments as U.S. access expands are structural payer dynamics that reduce realized revenues per unit. Over time higher rebate intensity and formulary negotiating power can erode margins on high-volume drugs, making revenue growth less accretive to cash flow unless offset elsewhere.
Loss Of Exclusivity RiskLOE for BRIVIACT is a structural revenue decline vector as generics enter and pricing and volumes fall. Even with new growth drivers, permanent erosion of an established product’s sales requires successful pipeline commercialization or partnerships to replace lost cash flow over the medium term.
UCB SA News
UCBJY FAQ
What was UCB SA’s price range in the past 12 months?
UCB SA lowest stock price was $96.14 and its highest was $168.70 in the past 12 months.
What is UCB SA’s market cap?
UCB SA’s market cap is $56.35B.
When is UCB SA’s upcoming earnings report date?
UCB SA’s upcoming earnings report date is Jul 30, 2026 which is in 24 days.
How were UCB SA’s earnings last quarter?
UCB SA released its earnings results on Feb 26, 2026. The company reported $3.785 earnings per share for the quarter, beating the consensus estimate of $3.16 by $0.625.
Is UCB SA overvalued?
According to Wall Street analysts UCB SA’s price is currently Overvalued.
Does UCB SA pay dividends?
UCB SA pays a Annually dividend of $0.85 which represents an annual dividend yield of 0.55%. See more information on UCB SA dividends here
What is UCB SA’s EPS estimate?
UCB SA’s EPS estimate is 2.71.
How many shares outstanding does UCB SA have?
UCB SA has 389,011,320 shares outstanding.
What happened to UCB SA’s price movement after its last earnings report?
UCB SA reported an EPS of $3.785 in its last earnings report, beating expectations of $3.16. Following the earnings report the stock price went down -7.921%.
Which hedge fund is a major shareholder of UCB SA?
Currently, no hedge funds are holding shares in UCBJY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
UCB SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.69%
12-Months-Change
Fundamentals
Return on Equity
15.16%
Trailing 12-Months
Asset Growth
18.72%
Trailing 12-Months
Company Description
UCB SA
UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases. Its primary product, Cimzia, addresses a spectrum of inflammatory TNF-mediated conditions, encompassing ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For epilepsy management, the company provides Vimpat, Keppra, and Briviact, alongside Nayzilam, an emergency nasal spray for seizure clusters. Neupro is offered for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal alleviate allergy symptoms. The portfolio further extends to Evenity, a treatment for osteoporosis in postmenopausal women, and BIMZELX, used for psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Dapirolizumab pegol is also available for systemic lupus erythematosus. UCB maintains a robust development pipeline featuring therapies such as rozanolixizumab for myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for stereotypic prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Additionally, the company engages in contract manufacturing services. UCB S.A. has forged collaborative agreements with partners including Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. Its operational presence spans the United States, Japan, Germany, a broader European footprint (including Spain, France, Italy, the United Kingdom, and Ireland), China, Belgium, and other global territories. Incorporated in 1925, the company's headquarters are situated in Brussels, Belgium.
UCBJY Company Deck
UCBJY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive operational and financial story: strong top-line growth, meaningful margin expansion, doubled EPS, sizable commercial traction for BIMZELX and other growth drivers, important regulatory wins (KYGEVVI) and pipeline momentum. Challenges noted include net-price/gross-to-net pressure as access expands, near-term LOE for BRIVIACT, industry headwinds in clinical trials and competitive risks in several programs. On balance the positives (robust growth, profitability, pipeline progress and a strengthened balance sheet) outweigh the challenges, although execution on pricing, trial execution and competitive positioning will be important in 2026.View all UCBJY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---